「Targeted epigenetic induction of mitochondrial biogenesis enhances antitumor immunity in mouse model」の関連論文
-
Inactivation of the PD-1-dependent immunoregulation in mice exacerbates contact hypersensitivity resembling immune-related adverse events
-
Studies on programmed death-ligand 1 in equine and swine diseases [an abstract of entire text]
-
Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
-
In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy
-
A study on the immunostimulatory effects of alarmin HMGN1 in cancer immunity
-
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
-
Clinical efficacy of the combined treatment of anti-PD-L1 rat-bovine chimeric antibody with a COX-2 inhibitor in calves infected with Mycoplasma bovis
-
Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3 (本文)
-
Research for elucidation of immune evasion mechanisms and development of a novel immunotherapy for cancer in dogs [an abstract of entire text]
-
The fruits of CD40 research in basic and clinical medicine will soon be harvested
-
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer
-
Survival Analyses Based on Tumor Microenvironment Profile in Endometrial Carcinoma
-
Study on the regulation of CD8+ T cell immune response through nuclear receptor RORα and REV-ERB [an abstract of entire text]
-
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
-
Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model
-
Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model
-
Oncolytic herpes simplex virus HF10 (canerpaturev, C-REV) promotes accumulation of CD8^+PD-1^- tumor-infiltrating T cells in PD-L1–enriched tumor microenvironment
-
Generation of molecular-targeting peptides for selective inhibition of the interaction between CTLA-4 and B7 in the dog: a new immune checkpoint inhibitor for cancer therapy
-
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma (本文)
-
Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal
-
An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
-
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
-
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
-
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer
-
Characterization of the Anticancer Activities of Some Natural and Synthetic Compounds: Molecular Targets and Mechanism
-
Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine
-
Identification of T cell receptors targeting a neoantigen derived from recurrently mutated FGFR3
-
Studies on the Enhancement of Antitumor Effect by Drug Combination in Molecular-Targeted Therapy of Cancer
-
Molecular design of dendrimers with anionic terminal groups for delivery to various lymph node-resident cells
-
PD-L1 on mast cells suppresses effector CD8⁺ T-cell activation in the skin in murine contact hypersensitivity
-
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
-
CD204‑positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand‑1 expression
-
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients
-
Everolimus delayed and suppressed cytomegalovirus DNA synthesis and the spread of infection and alleviated cytomegalovirus infection
-
The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells
-
Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms
-
THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer
-
PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study
-
PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study
-
Lusutrombopag effectively promotes the growth and differentiation of megakaryocytic cells from patients with myelodysplastic syndrome
-
肺がん細胞の senolysis とferroptosis において 細胞質 p21Cip1/Waf1 は防御的に作用する
-
Paradoxical activation of c-Src as a drug-resistant mechanism
-
Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model.
-
Efficacious Combination Drug Treatment for Colorectal Cancer that Overcomes Resistance to KRAS G12C Inhibitors
-
Preclinical Evaluation of Lymph Node Targeted Therapy in Mouse Models of Cancer
-
SEPSIS INDUCES DEREGULATION OF IL-13 PRODUCTION AND PD-1 EXPRESSION IN LUNG GROUP 2 INNATE LYMPHOID CELLS
-
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
-
Nrf2/p-Fyn/ABCB1 axis accompanied by p-Fyn nuclear accumulation plays pivotal roles in vinorelbine resistance in non-small cell lung cancer
-
Activation of BAX and BAK is an attractive combination therapy in melanoma
-
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells